Safety and effectiveness of remdesivir in COVID-19 patients with liver dysfunction: a retrospective cohort study
- 23 October 2025
- journal article
- research article
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-12
Abstract
Objective This study aimed to assess the safety and effectiveness of remdesivir in hospitalized COVID-19 patients with liver dysfunction. Methods A retrospective cohort study analyzed medical records of 268 patients hospitalized between 2019 and 2022 with COVID-19 and elevated liver enzymes (AST and ALT). Patients were divided into remdesivir (N = 134) and non-remdesivir (N = 134) groups. Outcomes assessed included in-hospital mortality, 30-day mortality, adverse events, time to clinical improvement, and time to discharge. Statistical analyses included logistic regression with significance at p < 0.05. Results A total of 268 patients (134 receiving remdesivir and 134 controls) were included. The remdesivir group was older, had lower oxygen saturation, and presented with more severe disease at baseline. Despite these differences, remdesivir use was associated with a significantly faster clinical recovery (adjusted β = − 2.18 days; 95% CI: − 4.206 to − 0.154; p = 0.035). In-hospital mortality was higher in the remdesivir group (10.45% vs. 7.46%), but this difference was not statistically significant after adjustment (OR 0.12; 95% CI: 0.001–8.390; p = 0.109). Remdesivir nearly doubled the risk of serious adverse events (OR 1.90; 95% CI: 0.988–3.656), although this did not reach statistical significance (p = 0.054). Independent predictors of death or major adverse events included ICU admission, elevated ALP, and concomitant use of certain medications. Conclusion Remdesivir appears safe in COVID-19 patients with liver dysfunction and significantly shortens time to clinical improvement without increasing mortality or serious adverse events.Keywords
This publication has 34 references indexed in Scilit:
- WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity ScalesJournal of General Internal Medicine, 2022
- Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19JAMA Network Open, 2021
- Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19JAMA Network Open, 2021
- Safety of Remdesivir in Patients With Acute Kidney Injury or CKDKidney International Reports, 2021
- Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic ImpairmentDrugs in R&D, 2020
- FDA approves remdesivir, first treatment for COVID‐19The Brown University Child & Adolescent Psychopharmacology Update, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- SARS-CoV-2 infection: The role of cytokines in COVID-19 diseaseCytokine & Growth Factor Reviews, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020